Under construction – not a live service
Sign in
Not yet recruitingNo phase

Elimination of Hepatitis C Virus Among Users of Substances

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Trial code
NCT05503979
Record updated
6 November 2026
Original description
Substance users are a vulnerable group that should be prioritized in HCV (Hepatitis C Virus) elimination efforts in Mexico and in which it is feasible to carry out micro-elimination programs. It is an important group to treat both because of its high prevalence and because of the dynamic spread of infection among the general population. HCV seropositivity has not been documented in this group of people in Mexico City, the metropolitan area and the northern states of the country, nor has the sustained viral response been evaluated in this group of patients in the Mexican population.Read full original descriptionShow less

Eliminación de la infección Por el Virus de la Hepatitis C en PWID en Los Estados Del Norte de México

Substance users are a vulnerable group that should be prioritized in HCV (Hepatitis C Virus) elimination efforts in Mexico and in which it is feasible to carry out micro-elimination programs. It is an important group to treat both because of its high prevalence and because of the dynamic spread of infection among the general population. HCV seropositivity has not been documented in this group of people in Mexico City, the metropolitan area and the northern states of the country, nor has the sustained viral response been evaluated in this group of patients in the Mexican population.

Inclusion: Patients older than 18 years; Active infection by hepatitis C virus; People who use substances and who are users of rehabilitation centers in Mexico City, the metropolitan area and the northern states of the country; Signature of informed consent.

Exclusion: all those who do not fit the inclusion criteria.

ClinicalTrials.gov NCT05503979